Anti-Complement C3b-iC3b [5G9] Antibody

This mouse IgG2a monoclonal antibody [5G9] was generated against human C3b-sepharose and reacts with human and primate complement component 3b (C3b) and iC3b; blocks activation of the classical pathway of complement.

Highlights

  • Reacts with both human and primate C3b and iC3b
  • Blocks activation of the classical pathway of complement
  • Suitable for Flow Cytometry and Neutralizing applications

The complement system consists of a number of small proteins found in the blood, generally synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex.

Complement component 3 (C3) plays a central role in the activation of the complement system. C3 cleavage by C3-convertase produces C3b and iC3b. C3b leads to an inflammatory response and also covalently binds to microbial cell surfaces aiding in opsonization of the microbe.

From the laboratory of Ronald P. Taylor, PhD, University of Virginia

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product Size AVAILABILITY Price Qty
EG1007
Anti-Complement C3b-iC3b [5G9] Antibody
100ug In stock
Regular Price:$378.00
Specifications

Product Type: Antibody
Antigen: C3b
Accession ID: NP_000055
Isotype: IgG2a
Clonality: Monoclonal
Clone Name: 5G9
Reactivity: Primate, Human
Immunogen: Human C3b -Sepharose
Species Immunized: Mouse
Epitope: Human complement component 3b (C3b) and iC3b
Purification Method: Protein G Affinity
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: Neutralizing and Flow Cytometry
Comments: 5G9 blocks activation of the classical pathway of complement
Storage: -20C
Shipped: Cold packs

Provider
From the laboratory of Ronald P. Taylor, PhD, University of Virginia
References
  1. Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010 Mar 18;115(11):2283-91.
  2. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol. 2012 Apr 1;188(7):3532-41.

If you publish research with this product, please let us know so we can cite your paper.

Loading...